ZBD(SH:603567) Zheng Quan Ri Bao Wang·2025-04-30 07:42Core Insights - The company reported a revenue of 2.704 billion yuan and a net profit attributable to shareholders of 438 million yuan for the year 2024, with a 20.23% year-on-year growth in pharmaceutical industrial revenue driven by optimized marketing strategies [1] Group 1: Financial Performance - In 2024, the company achieved a revenue of 2.704 billion yuan and a net profit of 438 million yuan [1] - The pharmaceutical industrial revenue grew by 20.23% year-on-year due to enhanced marketing model adjustments [1] Group 2: Market Participation and Product Offerings - The company actively participated in national drug procurement projects, securing 14 core specifications in the third batch of national traditional Chinese medicine procurement [1] - A total of 86 products from the company were included in the latest national medical insurance directory, with 35 classified as Category A and 51 as Category B [1] Group 3: Marketing Strategy and Network Development - The company has established a nationwide marketing network covering over 6,000 medical institutions across more than 30 provinces, integrating a full-chain service system from urban public hospitals to retail terminals [3] - The marketing strategy focuses on cardiovascular and respiratory diseases while expanding into pediatric and digestive health markets, utilizing diverse sales channels and marketing strategies to drive growth [2][3] - The company emphasizes a comprehensive marketing approach with a focus on sales capability enhancement across different business units, targeting commercial sales, medical terminal markets, and retail pharmacies [3]